Results 71 to 80 of about 80,637 (252)

Nivolumab-induced interstitial lung disease in the patient with melanoma

This article presents the case of a drug-induced interstitial lung disease in response to nivolumab, which is a programmed death receptor 1 (PD1) blocking antibody.
Marcin Morawski, Gabriela Trąd, Agnieszka Gawlewicz-Mroczka   +2 more
core   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma

Urology Case Reports, 2020
In the Checkmate-025 trial, nivolumab treatment prolonged overall survival among patients with previously treated advanced renal cell carcinoma (RCC) compared with treatment with everolimus. Although effective, nivolumab is associated with immune-related
Shinro Hata, Satoki Abe
doaj   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller, Christine Crearie, Liya Lu, Jiafeng Pan, Fraser N. Sneden, David Martin, Amanj Kurdi, Catherine S. Thomson, Julie Clarke, Marion Bennie   +9 more
wiley   +1 more source

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial

Cancer Medicine
Background First‐line nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated significant overall survival (OS) benefit versus chemotherapy in previously untreated patients with advanced esophageal squamous cell carcinoma (ESCC) in ...
Ken Kato, Yuichiro Doki, Ian Chau, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih‐Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Braghiroli, Eva Holtved, Tomoki Makino, Mariela Blum Murphy, Carlos Amaya‐Chanaga, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Yuko Kitagawa, Jaffer Ajani   +21 more
doaj   +1 more source

Checkpoint inhibition enhances cell contacts between CD4+ T cells and Hodgkin-Reed-Sternberg cells of classic Hodgkin lymphoma

Haematologica
Although checkpoint molecules like CTLA-4 and PD1 have been described several years ago, checkpoint inhibitors such as Nivolumab (an anti-PD-1 antibody) have only recently been used to treat classic Hodgkin lymphoma (cHL).
Kübra Yadigaroglu, Sonja Scharf, Steffen Gretser, Hendrik Schäfer, Aresu Sadeghi Shoreh Deli, Andreas G. Loth, Hasmik Yegoryan, Roland Schmitz, Emmanuel Donnadieu, Martin-Leo Hansmann, Sylvia Hartmann   +10 more
doaj   +1 more source

Nivolumab resistance in head and neck squamous cell carcinoma patients and future perspectives

Head and neck cancer (HNC) cases are increasing globally, with resistance to immunotherapies such as nivolumab posing a significant challenge. This systematic review examines the mechanisms of nivolumab resistance in HNC, with a focus on intrinsic tumor ...
Anna Mydlak, Bartosz Spławski, Jakub Zwoliński, Karolina Buchajska, Kinga Wojtaszczyk   +4 more
core   +1 more source

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [PDF]

, 2016
BACKGROUND: Treatments for small-cell lung cancer (SCLC) after failure of platinum-based chemotherapy are limited. We assessed safety and activity of nivolumab and nivolumab plus ipilimumab in patients with SCLC who progressed after one or more prior ...
Taylor, Matthew, C. T. Harbison, Harbison, Christopher T., M. A. Morse, Amin, Asim, de Braud, Filippo, M. . C. Pietanza, D. T. Le, E. Calvo, L. Horn, Calvo, Emiliano, P. Bono, A. Atmaca, J. A. López Martin, Chau, Ian, Christensen, Olaf, O. Christensen, Jäger, Dirk, J. Bendell, J. P. Eder, Ascierto, Paolo A., I. Chau, Pillai, Rathi N., Bono, Petri, Lin, Chen-Sheng, P. Sharma, Bendell, Johanna, P. A. Ott, Horn, Leora, Atmaca, Akin, F. de Braud, Sharma, Padmanee, Jaeger, Dirk, Evans, Jeffry, López-Martin, José A., Antonia, Scott J., Eder, Joseph Paul, Pietanza, M. Catherine, S. J. Antonia, J. Evans, Le, Dung T., C. Lin, P. A. Ascierto, A. Amin, D. Jäger, Morse, Michael A., Ott, Patrick A., M. Taylor, R. N. Pillai   +48 more
core   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source